François Mullier

Clinical laboratory hematology

Pr François MullierProf. François Mullier PharmD, PhD

CHU UCL Namur, Site Godinne, Hematology Laboratory

Member of the Institute of Experimental and Clinical Research (IREC), UCLouvain

Member of the Namur Thrombosis & Hemostasis Center (NTHC)

ORCID | ResearchGate | LinkedIn

Expertise and research interests

François Mullier holds a master's degree and PhD in Pharmaceutical sciences, and a complementary master in Clinical biology. He is head of the Department of Laboratory Medicine of the CHU UCL Namur (sites Dinant/Godinne) since 2019. He is also head of the Hematology-hemostasis laboratory since 2012 and coordinator of the Namur Thrombosis and Hemostasis Center (NTHC) at the CHU UCL Namur.

Teaching activites
  • Professor of "Clinical Biology" and "Biomarkers, Biobanks, Personalized Medicine" at the UNamur.
  • Professor of Hematology and Hemostasis Laboratory at the UCLouvain.
  • Teacher in the European course of laboratory medicine organized by the European Federation of Clinical Chemistry and Laboratory Medicine (Topic: Disseminated Intravascular Coagulation): 2022
  • Teacher of the European course on antithrombotic management CAS-AM since April 2022
Ohter functions
  • Co-Chair of the scientific Subcommittee (SSC) on control of anticoagulation of the International Society of Thrombosis and Hemostasis: 2023-2027
  • Member of the Hemostasis and Platelets committee of the International Society of Laboratory Hematology: 2022-2024
  • Member of steering committee of the European course on antithrombotic management CAS-AM (since November 2020)
  • Associate editor for Thrombosis Journal since March 2016
  • Member of the scientific committee of the “Revue Francophone Hémostase Thrombose” since March 2019
  • Editorial Board member for the Journal of Laboratory Medicine since April 2019
  • Editorial Board member for the Journal of Laboratory Precision Medicine since April 29th, 2022
  • Expert à l’institut belge de santé publique (cytologie, cytométrie et hémostase) (2014- en cours)
  • Membre fondateur et secrétaire du Namur Thrombosis and Hemostasis Center (2011- en cours)
  • Organisateur principal des 12 symposias annuels du Namur Thrombosis and Hemostasis Center (février 2011- en cours)
  • Président de la  « Commission de remboursement des analyses d’hématologie et hémostase biologique » depuis décembre 2022
  • President du groupe francophone d’utilisateurs du logiciel d’informatique laboratoire GLIMS depuis septembre 2016

Research project

  • ONGOING Relevance of the fibrinolysis and thrombin generation assay in the exploration of mild bleeding disorders  and bleeding of unknown cause. Ongoing PhD thesis by Marion Bareille. Under the supervision of Prof. François Mullier, CHU UCL Namur.
  • ONGOING Study of the mechanisms of catheter-associated thrombosis and its pharmacological mitigation using thrombin generation assay in the presence of platelets. Ongoing PhD thesis by Dr. Michaël Hardy. Under co-supervision by Prof. François Mullier, CHU UCL Namur (promoter) and Prof. Sarah Lessire, CHU UCL Namur (co-promoter).

   In collaboration with UNamur

  • ONGOING The MAS project: Measure And See the activity of direct oral anticoagulant in the clinical context. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Romain Siriez), Clinique Saint-Luc Bouge (Julien Favresse) and CHU UCL Namur (Prof. François Mullier and Dr. Michaël Hardy).

  • ONGOING The COVILAB project: Clinical laboratory investigations related to COVID-19. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Hélène Haguet, Constant Gillot and Laure Morimont), QUALIblood (Prof. Jonathan Douxfils, Céline Bouvy, Laure Morimont and Sabrina Melchionda), Clinique Saint-Luc Bouge (Julien Favresse), Hôpitaux Iris Sud (Dr. Marie Tre-Hardy), and CHU UCL Namur (Prof. François Mullier and Dr. Michaël Hardy).

Selected publications

Hardy M, Cabo J, Deliège A, Douxfils J, Gouin-Thibault I, Lecompte T, Mullier F. Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring. Res Pract Thromb Haemost. 2023 Nov 9;7(8):102257.

Mullier F, Baccini V, Lippi G, Lecompte T. Clinical studies on platelet transfusion: Time to consider methodological issues related to platelet counting. Transfusion. 2023 Nov;63(11):2198-2200.

Soleimani R, Khourssaji M, Cabo J, Guldenpfennig M, Baudar J, Chatelain B, Devalet B, Bareille M, Mullier F. Letter in response to Othman & Favaloro "Comparison of two ways of performing ristocetin-induced platelet agglutination (RIPA) mixing study for diagnosis of type 2B VWD". Res Pract Thromb Haemost. 2023 Aug 7;7(6):102165.

Bareille M, Lecompte T, Mullier F. Assessment of the individual determinants of two fibrinolysis assays, GFC and ECLT in platelet-depleted plasma and derived euglobulin fraction respectively. Thromb Res. 2023 Aug 13;230:33-36.

Wauthier L, Favresse J, Hardy M, Douxfils J, Le Gal G, Roy PM, van Es N, Ay C, Ten Cate H, Lecompte T, Lippi G, Mullier F. D-dimer testing: A narrative review. Adv Clin Chem. 2023;114:151-223.

Maschietto C, Otto G, Rouzé P, Debortoli N, Bihin B, Nyinkeu L, Denis O, Huang TD, Mullier F, Bogaerts P, Degosserie J. Minimal requirements for ISO15189 validation and accreditation of three next generation sequencing procedures for SARS-CoV-2 surveillance in clinical setting. Sci Rep. 2023 Apr 28;13(1):6934.

Hardy M, Michaux I, Bulpa P, Schonau B, Nicolay B, de Maistre E, Godon A, Lecompte T, Mullier F. Serial fibrin monomer and D-dimer plasma levels measurements can capture thrombotic complications in critically ill COVID-19 patients: A prospective observational study. Thromb Res. 2023 Jan;221:69-72.

Cabo J, Morimont L, Baudar J, Guldenpfennig M, Jacqmin H, Soleimani R, Lecompte T, Douxfils J, Mullier F. Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing. Int J Lab Hematol. 2023 Feb;45(1):126-136.

Bareille M, Hardy M, Chatelain B, Lecompte T, Mullier F. Laboratory evaluation of a new integrative assay to phenotype plasma fibrinolytic system. Thromb J. 2022 Dec 5;20(1):73.

Lardinois B, Hardy M, Michaux I, Horlait G, Rotens T, Jacqmin H, Lessire S, Bulpa P, Dive A, Mullier F. Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement. J Clin Med. 2022 Feb 28;11(5):1338.

Hardy M, Douxfils J, Morimont L, Didembourg M, Carlo A, de Maistre E, Lecompte T, Mullier F. Study of in vitro thrombin generation after neutralization of heparin. Int J Lab Hematol. 2022 Feb;44(1):168-176.

Douxfils J, Vayne C, Pouplard C, Lecompte T, Favresse J, Potier F, Gasser E, Mathieux V, Dogné JM, Gruel Y, Rollin J, Mullier F. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. Haematologica. 2021 Aug 12.

Sennesael AL, Larock AS, Hainaut P, Lessire S, Hardy M, Douxfils J, Spinewine A, Mullier F. The impact of strong inducers on direct oral anticoagulant levels. Am J Med. 2021 Oct;134(10):1295-1299.

Hardy M, Michaux I, Lessire S, Douxfils J, Dogné JM, Bareille M, Horlait G, Bulpa P, Chapelle C, Laporte S, Testa S, Jacqmin H, Lecompte T, Dive A, Mullier F. Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thromb Res. 2021 Jan;197:20-23.

Lessire S, Dincq AS, Siriez R, Pochet L, Sennesael AL, Vornicu O, Hardy M, Deceuninck O, Douxfils J, Mullier F. Assessment of low plasma concentrations of apixaban in the periprocedural setting. Int J Lab Hematol. 2020 Aug;42(4):394-402.

Douxfils J, Morimont L, Bouvy C, de Saint-Hubert M, Devalet B, Devroye C, Dincq AS, Dogné JM, Guldenpfennig M, Baudar J, Larock AS, Lessire S, Mullier F. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. J Thromb Haemost. 2019 Aug;17(8):1273-1287.

Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J, Bihin B, Chatelain B, Dogné JM, Chatelain C, Mullier F. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles. Medicine (Baltimore). 2019 Jul;98(27):e16164.

Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, Dogné JM, Mullier F. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018 Feb;16(2):209-219.

Godier A, Dincq AS, Martin AC, Radu A, Leblanc I, Antona M, Vasse M, Golmard JL, Mullier F, Gouin-Thibault I. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017 Aug 14;38(31):2431-2439.

Wannez A, Devalet B, Bouvy C, Laloy J, Bihin B, Chatelain B, Chatelain C, Dogné JM, Mullier F. Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thromb Res. 2017 Jun 9;156:142-148.

Minet V, Baudar J, Bailly N, Douxfils J, Laloy J, Lessire S, Gourdin M, Devalet B, Chatelain B, Dogné JM, Mullier F. Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. Thrombosis research 2014, 133:1074-1078.

Contact

francois.mullier@chuuclnamur.uclouvain.be